What PE Firms Look for in ABA Revenue Cycle During Diligence

Growth gets you the meeting. Revenue cycle performance determines the exit.

Most ABA founders assume growth is what attracts investors. It is what gets you the first conversation. But the capital, and the multiple, follow something quieter: predictable scope, operational discipline, and high-quality earnings. Nowhere does that show up more clearly than in your revenue cycle.

This is the third and final piece in our series, From Revenue Leakage to Exit-Ready ABA Operations. [Part 1] covered how to audit your ABA revenue cycle in 30 days. [Part 2] examined the tradeoffs between centralized and decentralized billing across multi-location operations. This piece brings those threads together through the lens that matters most when capital is on the table.

[fs-toc-omit]Core Insights

• Buyers now scrutinize revenue cycle with the same rigor they apply to staffing and lease liabilities, because leakage suppresses EBITDA invisibly.
• Five metrics carry the most weight: net collection rate, AR aging, denial trends, authorization management, and reporting infrastructure.
• Revenue cycle problems rarely kill a deal. They quietly re-price it through EBITDA restatements, AR haircuts, and escrow holdbacks.
• The strongest platforms did not fix these things for a transaction. They fixed them because it made the business run better.

Why revenue cycle became a diligence priority

Ten years ago, a PE firm evaluating an ABA platform focused on clinical outcomes, payor mix, and EBITDA margins. Revenue cycle was treated as back office, important but not determinative.

That has changed materially. ABA billing has grown genuinely complex: payor-specific authorization protocols, evolving documentation requirements, state-level Medicaid variation, and periodic commercial rate renegotiations all create risk that flows straight to EBITDA. After a wave of post-close revenue surprises, buyers now evaluate ABA revenue cycle with the same scrutiny they apply to staffing and lease liabilities.

Consider a platform generating $8M in gross revenue at a 94% net collection rate. That is roughly 6%, about $480,000 a year, left uncollected on what the business is contractually owed. Capitalized at a typical 8x multiple, that recurring leakage represents close to $4M in lost enterprise value. Most of it stays invisible until diligence begins, at which point it becomes the buyer's negotiating leverage, not yours.

The five areas PE firms evaluate during revenue cycle diligence

These are the areas where buyers scrutinize to the core when they find problems.

1. Net collection rate (NCR)

Why it matters: NCR is the single clearest indicator of revenue integrity. It measures what you actually collect against what you are contractually entitled to collect, after legitimate contractual write-offs.

What good looks like: A well-run ABA platform operates at 97%-99%. As a benchmark, Plutus Health targets a 98% NCR for the organizations it manages.

Red flags: NCR below 95% points to significant write-offs, weak denial follow-through, or aggressive contractual adjustments masking collection failure. Buyers will normalize this and restate EBITDA accordingly.

2. AR aging and accounts receivable management

Why it matters: AR aging reveals how efficiently services rendered convert into cash collected. It is also a direct proxy for operational discipline.

What good looks like: Days Sales Outstanding (DSO) of <35 days, with less than 15% of total AR being over 60 days.

Red flags: More than 25-30% of total AR over 60 days, DSO over 50 days, with large aging buckets.

3. Denial management and denial trends

Why it matters: Denial rate tells a buyer whether your front-end (documentation, coding, intake) is functioning and in sync. A rising denial rate indicates leakage, which causes internal damage by the time it surfaces.

What good looks like: Denial rates below 5% across all payors, with a structured, documented appeal process and a healthy appeal overturn rate.

Red flags: Denial rates above 10 %, widening variance across locations, and low appeal rates. Buyers read low appeal rates as operational passivity, revenue you were entitled to and chose not to pursue.

4. Authorization management

Why it matters: In ABA, the authorization is the revenue contract. Every hour billed without a valid authorization is a write-off waiting to happen. This is where clinical documentation and revenue cycle intersect, and where small lapses prove most expensive.

What good looks like: Client and payor authorization tracking in real time; automatic expiration reminders at 30, 60, and 90 days; no tolerance for out-of-hours billing.

Red flags: Manual spreadsheet management of authorizations, lack of consistent policies, and any proof from the audit sample of improper billing.

5. Reporting infrastructure and operational visibility

Why it matters: A buyer acquiring a multi-location platform is not just buying today's revenue. They are buying the platform's ability to scale. Reporting maturity is a direct signal of that. If the CFO cannot pull real-time performance across every location in under five minutes, there is a visibility problem, and visibility problems get priced in.

What good looks like: Unified dashboards with both location-level and aggregate views, automated AR aging, denial tracking by payor and reason code, and monthly KPI reporting that does not require a person to assemble by hand.

Red flags: Monthly reports that take weeks to consolidate across locations, no standard KPI set, and a business run out of one analyst's spreadsheet.

As ABA organizations scale, revenue cycle consistency becomes increasingly important. Leadership teams need clear visibility into collections, denials, authorizations, and AR performance across every location. When those processes are standardized and measurable, the organization is in a much stronger position to support growth and demonstrate operational maturity.

Revenue cycle red flags that trigger investor concern

Beyond the five core areas, experienced buyers look for structural vulnerabilities that compound risk post-close. These patterns recur across ABA diligence processes:

• Key-person dependency. When one or two people hold knowledge of payer relationships, appeal workflows, or authorization protocols, buyers price in transition risk. A billing coordinator who leaves takes institutional memory out the door, and buyers know it.
• Inconsistent payer management across locations. When each site runs different payer protocols, you get compliance exposure and revenue variability that is very hard to underwrite.
• No structured denial appeal process. Informal or location-dependent appeals signal leakage at scale.
• Manual processes at scale. Spreadsheet-based authorization tracking, manual AR reconciliation, and siloed billing systems tell a buyer that you are one bad quarter away from a cash flow crisis.
• Declining clean claim rates. A first-pass rate trending down over 12 months signals deteriorating front-end documentation, which is both a clinical and an operational problem.
• AR concentration in a single payor or state. Heavy revenue concentration in a single commercial payor or a single Medicaid state creates rate and renewal risk that buyers discount heavily.

A realistic diligence scenario, and what it costs

The following is an illustrative composite based on common diligence findings, not a single client.

A PE sponsor is evaluating an 11-location ABA platform generating $14M in annual revenue. Management presents a clean EBITDA of $2.1M and a compelling growth story. The LOI is signed. Diligence begins.

The QoE team pulls 24 months of AR aging across all locations. What they find:

• DSO ranges from 38 days at the best clinic to 74 days at the worst.
• Three locations carry AR buckets over 90 days totaling $680K.
• On the oldest claims sampled, 40 % show no documented appeal activity.
• Denial management is informal and location-specific. Two clinics are not appealing denials at all.
• One clinic's billing coordinator recently resigned, taking the Medicaid authorization workflow knowledge with her. That location's denial rate has averaged 23% over the last 90 days.

The buyer does not walk away. But they do three things:

• Apply a $420K AR haircut to the working capital peg.
• Reduce normalized EBITDA by $310K for recoverable revenue leakage.
• Add a $500K escrow holdback tied to revenue cycle performance targets for the 12 months post-close.

Total valuation impact from revenue cycle issues alone: roughly $2.5M, on a platform where none of these problems had been flagged before diligence began.

That is the cost of finding out what your revenue cycle looks like at the same time the buyer does.

How AI is changing revenue cycle diligence

The most sophisticated ABA operators no longer wait for a QoE team to tell them what their revenue cycle looks like. They use AI-powered revenue cycle intelligence to hold a continuous, real-time picture of performance and to fix problems before they become diligence liabilities.

• Denial trend analysis. Agentic AI, trained on years of ABA claims data, isolates denial patterns by payor, reason code, provider, and location, surfacing root causes that would take an analyst days to uncover. Plutus Health's OlympusAI is trained on 15-plus years of data and 800-plus payer interfaces.
• Predictive leakage detection. AI agents flag high-risk denials and likely AR write-offs before they age, enabling intervention rather than after-the-fact damage control.
• Authorization monitoring. Automated tracking of expirations, utilization against approved hours, and payor renewal timelines removes the manual gap where write-off risk lives.
• AR risk forecasting. Forward-looking AR models project cash flow 30 to 60 days out rather than reporting it after the quarter closes.
• Operational benchmarking. Real-time comparison across locations shows which clinics underperform and why, enabling targeted fixes rather than blanket policy changes.

Used this way, the same technology a buyer hopes to install post-close becomes what makes your numbers defensible before they ever make an offer. As a reference point, OlympusAI is designed to maintain a denial rate under 5% (25 AR days), a 48-hour turnaround, and a 98% net collection rate, with people focused on high-judgment work. At the same time, the agentic workflow handles the routine.

What best-in-class ABA organizations do differently

The platforms that perform best in diligence share a profile. Critically, they did not build it for a transaction. They built it because it made the business run better every day.

• Structured, recurring audits at the claim, payer, and location level, on a defined cadence, rather than waiting for problems to appear in the numbers.
• Centralized billing oversight. As covered in Part 2, the strongest performers have moved from decentralized billing toward a centralized or hybrid model with unified oversight, shared systems, and standard processes.
• Proactive AR management. Aging levels generate automatic alerts; claims aged 45-60 days receive structured follow-ups; and write-offs must be justified.
• AI-enabled visibility. Leadership can see performance across all locations in real time and spot an underperforming clinic before the monthly close.
• Accountability structures. There is clear ownership of each site for data accuracy and billing purposes, and performance against key performance indicators (KPIs) is evaluated monthly.

Quiz: Is your revenue cycle diligence-ready?

Answer honestly. Give yourself the points in brackets, then add them up to get your total score.

Is your revenue cycle diligence-ready?

Most ABA organizations have never assessed their revenue cycle against the benchmarks buyers actually use. If you are planning for growth, a recapitalization, or a future transaction, we offer a complimentary Revenue Cycle Diligence Readiness Review.

It covers the same five areas sophisticated buyers evaluate: net collection rate, AR aging, denial trends, authorization management, and reporting infrastructure. It takes less than two weeks and produces a clear picture of where you stand, where the risk is, and what to fix before a buyer finds it for you.